Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal CancerJin Li, Weiguo Su, Hongming Pan et al.|JAMA|2018Cited by 410
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO TrialJin Li, Shukui Qin, Weijian Guo et al.|Advances in Therapy|2020Cited by 28
Subgroup Analysis by Prior Anti-VEGF or Anti-EGFR Target Therapy in FRESCO, a Randomized, Double-Blind, Phase III trialRui‐Hua Xu, Jin Li, Shukui Qin et al.|Future Oncology|2020Cited by 8
Quality-Adjusted Survival in Patients with Metastatic Colorectal Cancer Treated with Fruquintinib in the FRESCO TrialShukui Qin, Lin Shen, Li Jin et al.|Future Oncology|2021Cited by 7
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal CancerShukui Qin, Jin Li, Rui‐Hua Xu et al.|OncoTargets and Therapy|2021Cited by 7